Inequalities in biologics utilization for rheumatoid arthritis according to socioeconomic status

참고문헌 (8)

1. Gravallese EM, "Rheumatoid arthritis-common origins, divergent mechanisms", N Engl J Med, 388, pp.529~542 (2023)
2. Breedveld FC, "Understanding emerging treatment paradigms in rheumatoid arthritis", Arthritis Res Ther, 13(Suppl 1), pp.S3~ (2011)
3. Schmajuk G, "Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans", JAMA, 305, pp.480~486 (2011)
4. Tatangelo M, "Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage", JAMA Netw Open, 2, pp.e1917053~ (2019)
5. Dixon WG, "Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register", Arthritis Rheum, 54, pp.2368~2376 (2006)
6. Verstappen SMM, "The impact of socio-economic status in rheumatoid arthritis", Rheumatology(Oxford), 56, pp.1051~1052 (2017)
7. Kotyla PJ, "Bimodal function of anti-TNF treatment : shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure?", Int J Mol Sci, 19, pp.1739~ (2018)
8. Kim HW, "Impact of socioeconomic status on biologics utilization in rheumatoid arthritis : revealing inequalities and healthcare efficiency", Korean J Intern Med, 39, pp.668~679 (2024)

관련 논문AI추천